Logo image of RGC

REGENCELL BIOSCIENCE HOLDING (RGC) Stock Price, Forecast & Analysis

USA - NASDAQ:RGC - KYG7487R1002 - Common Stock

13 USD
-0.68 (-4.97%)
Last: 11/13/2025, 8:00:02 PM
12.48 USD
-0.52 (-4%)
Pre-Market: 11/14/2025, 7:57:08 AM

RGC Key Statistics, Chart & Performance

Key Statistics
Market Cap6.43B
Revenue(TTM)N/A
Net Income(TTM)-4.09M
Shares494.49M
Float19.01M
52 Week High83.6
52 Week Low0.09
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)0
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO2021-07-16
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals


RGC short term performance overview.The bars show the price performance of RGC in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 -10 20 -20

RGC long term performance overview.The bars show the price performance of RGC in the last 1, 2 and 3 years. 1 year 2 years 3 years 2K 4K 6K

The current stock price of RGC is 13 USD. In the past month the price decreased by -27.58%. In the past year, price increased by 7958.72%.

REGENCELL BIOSCIENCE HOLDING / RGC Daily stock chart

RGC Latest News, Press Relases and Analysis

RGC Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 46.52 968.11B
JNJ JOHNSON & JOHNSON 18.81 470.23B
MRK MERCK & CO. INC. 10.55 232.12B
PFE PFIZER INC 8.06 146.63B
BMY BRISTOL-MYERS SQUIBB CO 7.41 98.98B
ZTS ZOETIS INC 19.11 53.70B
RPRX ROYALTY PHARMA PLC- CL A 9.67 23.17B
VTRS VIATRIS INC 4.68 12.72B
ELAN ELANCO ANIMAL HEALTH INC 22.91 10.92B
CORT CORCEPT THERAPEUTICS INC 86.08 7.98B
AXSM AXSOME THERAPEUTICS INC N/A 6.86B
LGND LIGAND PHARMACEUTICALS 27.61 3.94B

About RGC

Company Profile

RGC logo image Regencell Bioscience Holdings Ltd. engages in the research, development, and commercialization of traditional Chinese medicine. The company employs 12 full-time employees The company went IPO on 2021-07-16. The firm launches three liquid based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients.

Company Info

REGENCELL BIOSCIENCE HOLDING

11/F, First Commercial Building, 33-35 Leighton Road, Causeway Bay

Hong Kong 37918 HK

CEO: Yat-Gai Au

Employees: 12

RGC Company Website

RGC Investor Relations

Phone: 85221550823

REGENCELL BIOSCIENCE HOLDING / RGC FAQ

What does RGC do?

Regencell Bioscience Holdings Ltd. engages in the research, development, and commercialization of traditional Chinese medicine. The company employs 12 full-time employees The company went IPO on 2021-07-16. The firm launches three liquid based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients.


Can you provide the latest stock price for REGENCELL BIOSCIENCE HOLDING?

The current stock price of RGC is 13 USD. The price decreased by -4.97% in the last trading session.


Does RGC stock pay dividends?

RGC does not pay a dividend.


How is the ChartMill rating for REGENCELL BIOSCIENCE HOLDING?

RGC has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


Which stock exchange lists RGC stock?

RGC stock is listed on the Nasdaq exchange.


How many employees does REGENCELL BIOSCIENCE HOLDING have?

REGENCELL BIOSCIENCE HOLDING (RGC) currently has 12 employees.


RGC Technical Analysis

ChartMill assigns a technical rating of 3 / 10 to RGC. When comparing the yearly performance of all stocks, RGC is one of the better performing stocks in the market, outperforming 99.97% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

RGC Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to RGC. While RGC has a great health rating, there are worries on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

RGC Financial Highlights


Industry RankSector Rank
PM (TTM) N/A
ROA -54.68%
ROE -60.86%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%N/A
Sales Q2Q%N/A
EPS 1Y (TTM)100%
Revenue 1Y (TTM)N/A

RGC Forecast & Estimates


Analysts
Analysts63.4
Price TargetN/A
EPS Next YN/A
Revenue Next YearN/A

RGC Ownership

Ownership
Inst Owners0.14%
Ins Owners88.56%
Short Float %7.14%
Short Ratio5.74